Abstract
Adrenal incidentalomas (AI) are an escalating clinical issue due to the increasing use of imaging techniques. Occasional patients with AIs have been reported who have subsequently been diagnosed with congenital adrenal hyperplasia (CAH) due to CYP21A2 mutations (21-hydroxylase deficiency) or carrier status. The objective of this investigation was to describe a larger cohort of patients with AI suspected to be caused by 21-hydroxylase deficiency or carrier status. All patients with AI and suspected CYP21A2 mutations during the last decade at a single center in Stockholm, Sweden, were included. Nine patients were identified (54 ± 19-year-old at presentation). Two-thirds were females and two-thirds were from Sweden, while one-third was from the Middle East. Almost all (8/9) had children, but two had experienced fertility problems. Four of six women had symptoms of hyperandrogenism, and three had previously been diagnosed with polycystic ovary syndrome. The majority (7/9) had multiple AIs. In two cases, the initial suspicion had been adrenal cortical cancer, but increased urinary pregnanetriol had lead to the diagnosis of CAH. Basal serum 17-hydroxyprogesterone was 10 (1.75–338) nmol/L. Seven was diagnosed with CAH (six non-classic, one simple virilizing). Two patients were considered to be carriers. However, in four patients, no CYP21A2 mutation was found and thus no confirmation of the diagnosis could be achieved. Patient presented with multiple AIs with hyperandrogenism or a Middle East origin screening for CAH or carrier status may be indicated.
Similar content being viewed by others
References
G. Arnaldi, M. Boscaro, Adrenal incidentaloma. Best Pract. Res. Clin. Endocrinol. Metab. 26(4), 405–419 (2012). doi:10.1016/j.beem.2011.12.006
M. Terzolo, A. Stigliano, I. Chiodini, P. Loli, L. Furlani, G. Arnaldi, G. Reimondo, A. Pia, V. Toscano, M. Zini, G. Borretta, E. Papini, P. Garofalo, B. Allolio, B. Dupas, F. Mantero, A. Tabarin, AME position statement on adrenal incidentaloma. Eur. J. Endocrinol. 164(6), 851–870 (2011). doi:10.1530/EJE-10-1147
D.P. Merke, S.R. Bornstein, Congenital adrenal hyperplasia. Lancet 365(9477), 2125–2136 (2005). doi:10.1016/S0140-6736(05)66736-0
H. Falhammar, M. Thoren, Clinical outcomes in the management of congenital adrenal hyperplasia. Endocrine 41(3), 355–373 (2012). doi:10.1007/s12020-011-9591-x
A. Wedell, Molecular genetics of 21-hydroxylase deficiency. Endocr Dev 20, 80–87 (2011). doi:10.1159/000321223
H. Falhammar, M. Thoren, K. Hagenfeldt, A 31-year-old woman with infertility and polycystic ovaries diagnosed with non-classic congenital adrenal hyperplasia due to a novel CYP21 mutation. J. Endocrinol. Investig. 31(2), 176–180 (2008)
P.C. White, P.W. Speiser, Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr. Rev. 21(3), 245–291 (2000)
S. Jaresch, E. Kornely, H.K. Kley, R. Schlaghecke, Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J. Clin. Endocrinol Metab. 74(3), 685–689 (1992)
T.A. Bachega, A.E. Billerbeck, J.A. Marcondes, G. Madureira, I.J. Arnhold, B.B. Mendonca, Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin. Endocrinol. (Oxf.) 52(5), 601–607 (2000)
H. Falhammar, M. Thoren, An 88-year-old woman diagnosed with adrenal tumor and congenital adrenal hyperplasia: connection or coincidence? J. Endocrinol. Investig. 28(5), 449–453 (2005)
L. Barzon, P. Maffei, N. Sonino, C. Pilon, L. Baldazzi, A. Balsamo, O. Del Maschio, G. Masi, M. Trevisan, M. Pacenti, F. Fallo, The role of 21-hydroxylase in the pathogenesis of adrenal masses: review of the literature and focus on our own experience. J. Endocrinol. Investig. 30(7), 615–623 (2007)
M. Reincke, M. Peter, W.G. Sippell, B. Allolio, Impairment of 11 beta-hydroxylase but not 21-hydroxylase in adrenal ‘incidentalomas’. Eur. J. Endocrinol. 136(2), 196–200 (1997)
M. Toth, K. Racz, V. Adleff, I. Varga, L. Futo, C. Jakab, K. Karlinger, R. Kiss, E. Glaz, Comparative analysis of plasma 17-hydroxyprogesterone and cortisol responses to ACTH in patients with various adrenal tumors before and after unilateral adrenalectomy. J. Endocrinol. Investig. 23(5), 287–294 (2000)
H. Falhammar, H.F. Nystrom, U. Ekstrom, S. Granberg, A. Wedell, M. Thoren, Fertility, sexuality and testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 166(3), 441–449 (2012). doi:10.1530/EJE-11-0828
I. Nermoen, J. Rorvik, S.H. Holmedal, D.L. Hykkerud, K.J. Fougner, J. Svartberg, E.S. Husebye, K. Lovas, High frequency of adrenal myelolipomas and testicular adrenal rest tumours in adult norwegian patients with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin. Endocrinol. (2011). doi:10.1111/j.1365-2265.2011.04151.x
G. Russo, P. Paesano, G. Taccagni, A. Del Maschio, G. Chiumello, Ovarian adrenal-like tissue in congenital adrenal hyperplasia. N. Engl. J. Med. 339(12), 853–854 (1998). doi:10.1056/NEJM199809173391220
H. Selye, H. Stone, Hormonally induced transformation of adrenal into myeloid tissue. Am. J. Pathol. 26(2), 211–233 (1950)
F. Beuschlein, E. Schulze, P. Mora, H.P. Gensheimer, C. Maser-Gluth, B. Allolio, M. Reincke, Steroid 21-hydroxylase mutations and 21-hydroxylase messenger ribonucleic acid expression in human adrenocortical tumors. J. Clin. Endocrinol. Metab. 83(7), 2585–2588 (1998)
S.M. Baumgartner-Parzer, S. Pauschenwein, W. Waldhausl, K. Polzler, P. Nowotny, H. Vierhapper, Increased prevalence of heterozygous 21-OH germline mutations in patients with adrenal incidentalomas. Clin. Endocrinol. 56(6), 811–816 (2002)
L. Barzon, C. Scaroni, N. Sonino, F. Fallo, M. Gregianin, C. Macri, M. Boscaro, Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. J. Clin. Endocrinol. Metab. 83(1), 55–62 (1998)
P.W. Speiser, R. Azziz, L.S. Baskin, L. Ghizzoni, T.W. Hensle, D.P. Merke, H.F. Meyer-Bahlburg, W.L. Miller, V.M. Montori, S.E. Oberfield, M. Ritzen, P.C. White, Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 95(9), 4133–4160 (2010). doi:10.1210/jc.2009-2631
Acknowledgments
This study was supported by the Magn. Bergvalls Foundation, Swedish Endocrine Society, Karolinska Institutet and Stockholm County Council.
Conflict of interest
The author declares that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Falhammar, H. Non-functioning adrenal incidentalomas caused by 21-hydroxylase deficiency or carrier status?. Endocrine 47, 308–314 (2014). https://doi.org/10.1007/s12020-013-0162-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-013-0162-1